Hyderabad: MSN Group, a Hyderabad-based pharmaceutical company, is about to launch generic molnupiravir 200 mg capsules for the treatment of Covid-19 under the brand name Moluflow.
Molnupiravir is an oral Covid-19 antiviral drug indicated for the treatment of mild to moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing serious disease.
The MSN Group said, “Being an orally administered option, we are confident that this drug will increase treatment adherence and provide relief to Covid-19 patients. “
click here for more information on Hyderabad
Moluflow, which has received Emergency Use Approval (EUA) from DCGI, comes as a packet of 4 × 10 capsule strips with each 200 mg capsule. A dosage regimen of 800 mg (BID) for five days (four 200 mg capsules twice daily) is recommended in addition to standard medical care.
Moluflow is manufactured in MSN Group’s USFDA and MHRA accredited factory based in Hyderabad. The drug, issued on medical prescription, will soon be available in all retail pharmacies.
MSN Group, which successfully conducted molnupiravir clinical trials in India and presented its results to DCGI, was recently licensed by the Medicines Patent Pool (MPP) to manufacture and distribute MSD’s molnupiravir for the treatment of Covid-19.
This agreement will also help MSN Group to enable access to molnupiravir in more than 100 low and middle income countries (LMICs) following regulatory approvals from the respective countries.
Now you can get handpicked stories from Telangana today to Telegram everyday. Click on the link to subscribe.
Click to follow the Telangana Today Facebook page and Twitter .